Patents Assigned to Upjohn
  • Patent number: 6538035
    Abstract: The present invention is a method of treating an mammal selected from the group consisting of humans and horses who has asthma, COPD or allergic rhinitis and is in need of such treatment by inhaling an anti-asthma, anti-COPD anti-allergic rhinitis effective amount, respectively, of a compound selected from the group consisting of tolterodine hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: March 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Per-Goran Gillberg, Staffan Sundquist, Sue K. Cammarata
  • Patent number: 6531470
    Abstract: Oxazolidinones and methods for their synthesis are provided. Also provided are combinatorial libraries comprising oxazolidinones, and methods to prepare the libraries. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. The methods of library preparation include the attachment of oxazolidinones to a solid support. The methods of compound preparation in one embodiment involve the reaction of an iminophosphorane with a carbonyl containing polymeric support.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: March 11, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mikhail F. Gordeev, Gary W. Luehr, Dinesh V. Patel, Zhi-Jie Ni, Eric Gordon
  • Patent number: 6531139
    Abstract: The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic compounds.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: March 11, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Ping Gao, Walter Morozowich
  • Publication number: 20030045565
    Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: September 16, 2002
    Publication date: March 6, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao
  • Patent number: 6528301
    Abstract: The present invention related to microorganisms producing taxanes, such as paclitaxel or related taxanes, to the use of said microorganisms for the production of taxanes, and to the procedure for the isolation of said microorganisms from plants. In particular, the present invention relates to microorganisms of the Actinomycetes group producing taxanes as well as to the biologically pure cultures of a strain of the Actinomycetes group which produces taxanes. The microorganisms of Actinomycetes group are preferably belonging to the suprageneric groups of Streptomycetes, Actinoplanetes, Maduromycetes, Thermomonosporas or Nocardioforms, more preferably they are belonging to genus Streptomyces, Actinoplanes, Nocardiopsis, Micromonospora, Actinomadura or Kitasatosporia, still more preferably to the genus Kitasatosporia. A particularly preferred microorganism is Kitasatosporia sp. CECT 4991.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: March 4, 2003
    Assignee: Pharmacia & Upjohn SpA
    Inventors: Umberto Breme, Marinella Caruso, Nicoletta Crespi Perellino, Lorena Fedeli, Andrea Pavesi, Luca Piacenza, Giambattista Ventrella
  • Patent number: 6528678
    Abstract: A phosgene-free method for preparing a carbamate from a compound containing an amine group involves reacting the compound with an alkylating agent in the presence of carbon dioxide and cesium carbonate. A reaction can take place under standard pressure and temperature conditions and produces carbamates in a high yield with low by-product formation.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: March 4, 2003
    Assignee: Pharmacia& Upjohn Company
    Inventor: Byung H. Lee
  • Publication number: 20030040464
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K┐)/norepinephrine (K┐) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: September 26, 2002
    Publication date: February 27, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Erik H.F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
  • Patent number: 6525193
    Abstract: The present invention provides for aminoaryl oxazolidinone N-oxide compounds of Formula I wherein the variables are as defined herein. These compounds are exceedingly water soluble which is useful in preparing pharmaceutical formulations of these compounds. They are also rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp., and in organisms such as Mycoplasma spp.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: February 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert C. Gadwood, Bharat V. Kamdar
  • Patent number: 6525049
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: February 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
  • Patent number: 6521231
    Abstract: The present invention provides recombinant DNA molecules comprising a sequence encoding a pseudorabies virus (PRV) glycoprotein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gI, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRV, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: February 18, 2003
    Assignee: Pharamcia & Upjohn Company
    Inventors: Erik Aivars Petrovskis, Leonard Edwin Post, James G. Timmins
  • Patent number: 6518427
    Abstract: The present invention provides for aminoaryl oxazolidinone N-oxide compounds of Formula I wherein the variables are as defined herein. These compounds are exceedingly water soluble which is useful in preparing pharmaceutical formulations of these compounds. They are also rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp., and in organisms such as Mycoplasma spp.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: February 11, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert C. Gadwood, Bharat V. Kamdar
  • Patent number: 6518771
    Abstract: A method of monitoring contact burnoff in tap changers operating under load in which the load current is measured and for nominal variation of the voltage of the particular tap parameters are stored which are used to calculate the burnoff rate per contact per switching operation. From these values the cumulative burnoff rate of both the switching contact and resistance contact are determined and compared with limits or threshold values.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: February 11, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Rainer Frotscher, Dieter Dohnal
  • Patent number: 6514529
    Abstract: The present invention provides a compressed tablet of an antibacterial oxazolidinone agent which provides high drug load and excellent bioavailability.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: February 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Ken Yamamoto, Homer Lin
  • Patent number: 6514968
    Abstract: The present invention provides aminoalkoxy carbazole derivatives, and more specifically, provides compounds of formula (I) wherein R1, R2, R3, R4, R8 and R9 are described herein. These compounds are 5-HT ligands, and are useful for treating diseases wherein modulation of 5-HT activity is desired.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: February 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Ruth Elizabeth TenBrink
  • Patent number: 6515135
    Abstract: The present invention provides for aminoaryl oxazolidinone N-oxide compounds of Formula I wherein the variables are as defined herein. These compounds are exceedingly water soluble which is useful in preparing pharmaceutical formulations of these compounds. They are also rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp., and in organisms such as Mycoplasma spp.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: February 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert C. Gadwood, Bharat V. Kamdar
  • Publication number: 20030023031
    Abstract: According to the invention, there is provided a method of manufacturing a medicament for use in the treatment of cancer or viral infections which comprises obtaining a cancer treating effective amount of a compound of formula (I), 1
    Type: Application
    Filed: July 17, 2002
    Publication date: January 30, 2003
    Applicant: Pharmacia & Upjohn S.p.A.
    Inventors: Paolo Cozzi, Italo Beria, Giovanni Biasoli, Marina Caldarelli, Laura Capolongo, Cristina Franzetti
  • Patent number: 6512112
    Abstract: The present invention provides for aminoaryl oxazolidinone N-oxide compounds of Formula I wherein the variables are as defined herein. These compounds are exceedingly water soluble which is useful in preparing pharmaceutical formulations of these compounds. They are also rapidly converted back to the parent amines in vivo, making them useful as prodrugs of the parent amines. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp., and in organisms such as Mycoplasma spp.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: January 28, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert C. Gadwood, Bharat V. Kamdar
  • Patent number: 6511813
    Abstract: Disclosed are novel methods of using elongation factor p (efp) and related constituents of ribosomal complexes which comprise efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: January 28, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Keith R. Marotti, Roger A. Poorman, Peter A. Wells, Dean L. Shinabarger
  • Patent number: 6509491
    Abstract: The present invention is a process to prepare on of a phenylisoserine ester of the formula (II) &phgr;—CH(NH—CO—CH3)—CH(OH)—CO—O—R1 with reduced amount of diol by-product by the use of a compound of the formula R2—CO—NH2 where R2 is C1-C6 alkyl with the proviso that R2 is not tertiary.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: January 21, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Peter Guillaume Marie Wuts
  • Patent number: 6503920
    Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: January 7, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Baltazar Gomez-Mancilla